Surveillance of Patients With Adenocarcinoma of the Gastroesophageal Junction or Esophagus
NCT ID: NCT02991547
Last Updated: 2024-02-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
3 participants
OBSERVATIONAL
2016-12-31
2018-08-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Comparison of Systematic Surgery Versus Surveillance and Rescue Surgery in Operable Oesophageal Cancer With a Complete Clinical Response to Radiochemotherapy
NCT02551458
Pre-operative Chemotherapy and Radiation Therapy for Esophageal Carcinoma
NCT00230451
Evaluation for the Individualization of Therapy in Adenocarcinomas of the Gastroesophageal Junction
NCT02287129
Chemotherapy, Radiation Therapy, and Cetuximab Followed by Surgery, Docetaxel, and Cetuximab in Treating Patients With Esophageal Cancer or Gastroesophageal Junction Cancer
NCT00551759
An Open-label, Single-center, Phase 1/ 2 Study of Chemoradiotherapy and AT-101 in Patients With Locally Advanced Esophageal or Gastroesophageal Junction Cancer
NCT00561197
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Observational
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Received no previous treatment for esophageal cancer.
* Measurable or evaluable disease
* ECOG performance status: 0 to 2 that is able to perform activities of daily living with minimal assistance
* Adequate bone marrow function (hemoglobulin ≥8 g/dl, neutrophil ≥1.5x109/L and platelet ( ≥100x109/L)
* Adequate liver function
* Bilirubin normal, Meets 1 of the following criteria:
* Alkaline phosphatase (AP) normal AND AST/ALT ≤ 5 times upper limit of normal (ULN)
* AP ≤ 2.5 times ULN AND AST/ALT ≤ 1.5 times ULN
* AP ≤ 5 times ULN AND AST/ALT normal
* Adequate kidney function (creatinine ≤1.5 UNL and creatinine clearance ≥ 60 )
* Be at least 4 weeks from recent major surgical procedures.
* Patients must be able to understand the nature of the study and give written informed consent
* At least one measurable lesion on CT, MRI or esophageal barium exam.
Exclusion Criteria
* Contraindication for irradiation: complete obstruction of esophagus, deep esophageal ulcer, fistula to mediastinum, or hematemesis
* Participating in other clinical trials
* Pregnancy
* Clinically significant and uncontrolled major medical conditions including but not limited to active uncontrolled infection, symptomatic congestive heart failure, unstable angina pectoris or cardiac arrhythmia, psychiatric illness/ social situation that would limit compliance with study requirements
* any medical condition, which in the opinion of the study investigator places the subject at an unacceptably high risk for toxicities
18 Years
80 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
The Guthrie Clinic
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Joyson Poulose, MD
Role: STUDY_DIRECTOR
Guthrie Medical Group, PC/Robert Packer Hospital
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Guthrie Corning Hospital
Corning, New York, United States
Guthrie Medical Group, PC/Robert Packer Hospital
Sayre, Pennsylvania, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
1611-55
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.